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Pharmacogenomics

Antidepressant Dosing in Major Depression:
A Pharmacogenomic Approach
Morgan Homan, Haval Norman, Victoria Cho, YousifRojeab, Ph.D.

Abstract
Major depressive disorder (MDD) is the most predominant
mental disorder in the United States, with serious and costly
health risks if not successfully managed. Pharmacotherapy is
a standard option for MDD treatment, but patients often require extensive therapy adjustments to find a suitable regimen. Pharmacogenomics may enable greater precision in
antidepressant therapy. Genotypic variations in CYP2D6 and
CYP2C19 metabolic enzymes are reliable predictors of serum
drug concentration, but the complex dose-response relationship of antidepressants prevents such variations from predicting therapy success. Additionally, ABCBl has been examined for its role in P-glycoprotein efflux of antidepressants in
the brain, yet it is still inconclusive as to which variations are
correlated with drug response. Current genotypic guidelines
are largely proactive and clinical trials utilizing genotypic
dosing have shown significant reductions in side effects and
health care costs. Further studies of genotypic targets are
needed and, if the possible clinical benefits are confirmed,
the use of genotyping will be an important tool in optimizing
antidepressant therapy.
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Depression Background
The National Institute of Mental Health (NIMH) defines major depressive disorder (MOD) as "severe symptoms that interfere with your ability to work, sleep, study, eat and enjoy
life. An episode may occur only once in a person's lifetime, but
more often a person has several episodes."1 Depression can be
caused by a multitude of factors, a few of which include environmental, genetic, psychological and biological influences.
Patients with MOD typically experience a low quality of life.2
Often, depressed patients experience a decrease in physical,
social and role functioning more than individuals with other
chronic conditions such as diabetes or osteoarthritis. Patients
with MDD often report poor intimate relationships, poor social
interactions and social irritability. These individuals typically
have a greater household or financial strain as well. It is also
common for depression patients to experience limitations in
the workplace, exhibit poor overall health and have a higher
level of missed days of work.
Major depressive disorder is the most prevalent mental
health disorder in the United States.3 It is estimated that 6.7
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percent of adults in the United States experienced a major
depressive episode in 2014. The female population was more
likely to experience these episodes (8.2 percent) versus the
male population (4.8 percent). Major depressive episodes
were also more prevalent in adults aged 18 to 25 years (9.3
percent) compared to adults aged 26 to 49 years (7.2 percent) and those aged 50 years and older (5.2 percent). The
prevalence of MOD was even greater in adolescents aged 12
to 17 years (11.4 percent) than in adults in 2014. In this adolescent age group, the female population was also more likely
to experience a major depressive episode (17.3 percent) than
males (5.7 percent). Prevalence in adolescents increased
with age. Twelve-year-olds had a prevalence of 5. 7 percent
while 17-year-olds had a prevalence of 15.1 percent.
While MOD varies between patients, the NIMH identifies several signs and symptoms that may indicate the onset of depression.1 A few of these include feelings of hopelessness,
pessimism, guilt, worthlessness, fatigue, decreased energy,
insomnia and persistent sad, anxious or empty feelings. A
depressed patient may also experience thoughts of suicide,
have difficulty concentrating, making decisions and remembering details.
The diagnosis criteria for MOD has been described by the
American Psychiatric Association (APA) in the fifth edition of
the Diagnostic and Statistic Manual of Mental Disorders
(DSM-5).4 The diagnosis criteria are summarized in Table 1.
It is important to note that an individual responding to a significant loss, such as financial or loss of a loved one, may exhibit some of the criteria specified in section A of Table 1;
therefore, the medical professional's clinical judgment must
be exercised to determine if this constitutes a major depressive episode.
Upon diagnosis of MOD, the APA recommends psychiatric
management which includes establishing and maintaining a
therapeutic alliance.s The patient should undergo a
psychiatric assessment and be evaluated for safety, functional impairment and quality of life. The patient's care should be
coordinated with other clinicians, and his or her psychiatric
status should be monitored. The health care team should
integrate measurements into psychiatric management, assist
with treatment adherence and provide education to the
patient and the family.
The acute phase of MOD treatment begins with the initiation
of treatments This often constitutes the introduction of pharmacotherapy but may also include depression-focused psychotherapy, a combination of the two, electroconvulsive
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Table 1. Diagnostic Criteria of Major Depressive Disorder (MDD). 4

A. The patient must demonstrate at least five of the following symptoms, which must have been present almost every day
during a consecutive 14-day period. It is important to point out that these symptoms must demonstrate a change from
the patient's normal functioning. These symptoms may be given as a subjective report or as observed by others. Several
of the diagnosis criteria may present differently in children as noted below.

The patient must
demonstrate at least one
of the following.

• Depressed mood for the majority of the day. (Note: In children and adolescents, may
present as irritable mood.)
• Noticeably decreased interest or pleasure in all, or nearly all, activities for the majority
of the day.

The patient must
demonstrate at least four
of the following.

• Notable weight loss when not attempting to diet or weight gain or change in appetite.
(Note: In children, may present as failure to make expected weight gain.)

• Insomnia or hypersomnia.

• Psychomotor agitation or retardation (this criterion must be noted by others and not
solely based on subjective feelings of the patient of uneasiness or being slowed down).

• Fatigue or lack of energy.

• Feelings of inadequacy or excessive or inappropriate guilt (which may be deranged),
not solely self-blame or guilty feelings about being sick.

• Decreased ability to think, concentrate or make decisions.

• Frequent thoughts of death that expand beyond fear of dying, periodic suicidal
thoughts without a definitive plan, a suicide attempt or a definitive plan for committing
suicide.

B. The symptoms must cause a significant distress or impairment in normal daily functions such as social, occupational or
other important areas of operation.

c.

The symptoms exhibited must not be attributed to any other factor such as the psychological effects of a substance or a
symptom of another medical condition.

D. The major depressive episode as expressed above must not be better attributed to a psychotic disorder, including schizophrenic disorders.

E. The patient must not have experienced a manic or hypomanic episode. The exception to this criterion is ifthe episode
can be attributed to another medical condition.

Adapted from: American Psychiatric Association: Desk Reference to the Diagnostic Criteria from DSM-5. Arlington (VA): American Psychiatric Association; 2013. Major Depressive Disorder; p. 94-95.
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Monitoring of the patient should continue for several months
-------------------------------------------------------------------

therapy (ECT), transcranial magnetic stimulation (TMS) or
light therapy. For patients with mild to moderate MOD, the
APA recommends an antidepressant as initial treatment. In
individuals with severe MOD, the APA deems an antidepressant necessary for treatment unless the patient plans to
undergo ECT. The medications initially recommended for
depression patients include selective serotonin reuptake inhibitors (SSRls), serotonin norepinephrine reuptake inhibitors (SNR!s ), mirtazapine, or bupropion. The individual
agent, however, may be chosen based on anticipated side
effects, patient's ability to tolerate the drug, safety considerations targeted to the individual patient and pharmacologic
properties of the drug itself. These properties include the
half-life, drug-drug interactions and the drug's action on cytochrome P (CYP) 450 enzymes. Monoamine oxidase inhibitors (MAO!s) are typically reserved for patients who do not
respond to first-line treatments.

Careful monitoring should occur during the acute phase, and
dosage or drug modifications should be made based on side
effects or adverse events.s When assessing the efficacy of an
agent in a particular patient, the medication should be discontinued after one month if the patient shows no signs of
symptomatic improvement. If a patient is unresponsive or
only partially responsive after four to eight weeks, the drug
and dose should be adjusted and reevaluated in another four
to eight weeks. When adjustments are necessary, the dose is
titrated first as long as the patient has not experienced any
adverse events and the side effects are well-tolerated. If a
dose adjustment does not demonstrate any improvement,
the patient may be prescribed a different medication either
from the same class or another class of antidepressants. A
patient is considered to be in the acute phase of treatment
until he or she has demonstrated a response to medication. A
response may not appear with the first treatment choice, so
the acute phase is not limited to a specific time frame and
may continue for an extended period of time.
Once a patient has demonstrated some success with an agent
in the acute phase, he or she moves on to the continuation
phase.s Here, the patient is monitored for potential relapse
while on the medication initiated with success in the acute
phase. This drug is typically continued for four to nine
months, and the APA recommends depression-focused psychotherapy for prevention of relapse. A patient may move
onto the maintenance phase of therapy using the same agent
he or she used in the acute and continuation phases with success, but the medication may be adjusted to a full therapeutic
dose. The maintenance phase is strongly recommended for
patients who have high risk factors for recurrence of a major
depressive episode. These risk factors may include family
history of depression or mood disorders, presence of psychosocial triggers or appearance of lingering symptoms. Maintenance treatment continues indefinitely unless a patient and
physician come to the decision to discontinue treatment. If
pharmacologic treatment is discontinued, the dose should be
tapered to prevent relapse and discontinuation symptoms.
The patient should also be counseled on the signs of a relapse and have a plan in place if such an incident occurs.
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after discontinuation.

While there are many options for initiating antidepressant
therapy, adverse effects and poor efficacy often lead to a
game of trial and error. This can waste money and time on an
ineffective agent. It often takes at least one month to determine if the chosen treatment will be successful in a particular
patient, so it may take months to years for a patient to find
the right medication in the acute treatment phase to control
his or her MOD. Genomic testing can help determine how a
patient will react pharmacokinetically and pharmacodynamically to a particular drug and increase the likelihood of
choosing an effective drug therapy at the initiation of treatment.
CYP2D6 and CYP2C19 PK/PG

The CYP2D6 and CYP2C19 genes code for members of the
CYP450 liver enzymes, which are heavily involved in the metabolism of many antidepressant medications.6.7 CYP206
metabolism influences clearance of the SSRis fluvoxamine
and paroxetine and, also, tricyclic antidepressants (TCAs)
such as amitriptyline, clomipramine, desipramine, imipramine, nortriptyline and trimipramine. CYP2Cl 9 metabolism
is observed with SSRis including citalopram, escitalopram
and sertraline, as well as TCAs like amitriptyline, clomipramine, imipramine and trimipramine.
Both CYP2D6 and CYP2C19 have numerous polymorphisms
in the population, with some alleles coding for decreased or
increased activity compared to the standard function seen in
the most common genotypes.6,7 Combinations of these alleles
result in several phenotypic classes: poor, intermediate,
extensive and ultrarapid metabolizers. Two of the primary
concerns are that poor metabolizers build up higher plasma
concentrations of antidepressants and may be at greater risk
of toxicities and side effects, while ultrarapid metabolizers
may be more likely to experience treatment failure if plasma
concentrations are too low. Pharmacogenomic guidelines
have been developed and published for many SSRis and TCAs
to adjust dosage or recommend alternative therapies. However, the clinical significance for these guidelines is still being
debated and is additionally complicated by an uncertain dose
-response relationship of antidepressant medications.
A pair of studies by Hodgson and colleagues with information from the Genome-Based Therapeutic Drugs for Depression Project (GENDEP) questioned the association of
pharmacogenomic dosing and SSRI/TCA side effects and
treatment response.B.9 The first study examined 223 patients
on escitalopram and 161 patients on nortriptyline using a
pragmatic design and flexible dosing protocol, where serum
antidepressant concentration was assessed 8 weeks after
treatment. 8 Patients were additionally genotyped. Variation
in CYP2C19 significantly correlated with escitalopram concentration (p=9.35*10-9), while CYP2D6 genotype was significantly associated with nortriptyline levels (p=l.90*10-6).
Neither genotyping nor serum concentration was significantly related to treatment response for either medication. The
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second study examined the connection between CYP450 genotype and side effects with escitalopram and nortriptyline.9
No significant association was found between genotype and
side effects; serum concentration significantly predicted only
a few minor effects, including the risk of dry mouth (p=
0.0107), diarrhea (p=4.96*10-4) and dizziness (p=3.28*10·5)
with escitalopram, and dry mouth (p=0.0331) with nortriptyline. The authors acknowledged possible bias from the
pragmatic design and flexible dosing, recognizing limited
application of the results and the need for further study. This
study demonstrates, again, that CYP genotyping is ineffective
for predicting patient response.
ABCB1PK/PG
The ABCBl gene codes for the amino acid transporter
P-glycoprotein (P-gp) in many organs, including brain capillary endothelial cells where it drives out substrates and helps
maintain the blood-brain barrier (BBB).10 Many drug classes,
including the TCAs, SSRis and SNRI venlafaxine are substrates
for P-gp and have limited uptake into the brain because of this
efflux activity. Because of this limitation, genetic variation in
ABCBl could result in altered P-gp function and clinically significant changes in antidepressant distribution to the brain.

A 2015 meta-analysis by Breitenstein and colleagues examined 16 pharmacogenetic studies associating ABCBl variants
and antidepressant outcomes for MOD patients (n = 2,695).10
A total of six single nucleotide polymorphisms (SNPs) were
separately analyzed based on all studies, inpatient samples,
outpatient samples, Caucasian only samples and without comedication sub-groups. The SNP rs2032583 was associ2ted
with treatment outcomes across all studies (p = 0.035) and
among all inpatient subjects (p = 1.5*10-5), while SNP
rs2235015 was associated with treatment outcomes only
among all inpatient subjects (p = 3.0*10·4). Both of those
SNPs were intronic, meaning they did not alter the protein
structure of P-gp but may modify brain delivery of antidepressants through unknown mechanisms. It was noted that
the majority of the studies included did not have fixed dosages but were adjusted based on patient condition. If drug doses were decreased because of side effects, P-gp activity and
BBB penetration may have been reduced and remain undetected.
Schatzberg and colleagues genotyped 10 ABCBl SNPs in 683
MOD patients, including all six SNPs analyzed in the Breitenstein meta-analysis.11 Patients were randomized to treatment with escitalopram, sertraline or venlafaxine ER for at
least two weeks (576 subjects completed eight weeks of
therapy), with treatment efficacy assessed by the 16-item
Quick Inventory of Depressive Symptomatology- Self Rated
(QIDS-SR). Only SNP rs10245483 was significantly associated with prediction of remission (Wald statistic W=12.64,
p<0.001, odds ratio OR=3.48). Common allele (G) homozygotes had significantly better response to escitalopram
(p=0.032) and sertraline (p=0.020) than minor (T) allele
homozygotes, which had significantly better response to
venlafaxine (p=0.018); heterozygote genotypes had no significant differences across treatment. Similarly, major allele
Summer 2016 Volume 7, Issue 3

carriers had less adverse effects with escitalopram (p=0.037)
while venlafaxine was associated with fewer side effects in
minor allele homozygotes (p=0.017). The T minor allele has
been reported to cause higher P-gp expression and may
cause increased SSRI clearance, causing the observed, decreased efficacy. Venlafaxine activity as an SNRI may explain
why it was more effective with minor alleles. The researchers
acknowledged limitations in that serum drug concentrations
were not collected and how as a pragmatic study the dosages
were slightly lower than traditionally used in clinical drug
trials, which could have altered response.
Clinical Applications
While pharmacogenomic data continue to be collected, many
challenges remain in identifying factors significant to treatment outcomes. In addition to the studies specifically examining the genes coding for CYP enzymes or P-gp transporters,
several genome-wide association studies have attempted to
detect genetic variations connected with antidepressant outcome in MOD. The three largest were the GENDEP project,
the Munich Antidepressant Response Signature (MARS) project and the Sequenced Treatment Alternatives to Relieve
Depression (STAR*D) study.12 A meta-analysis of data by the
investigators of the three studies, including 2,256 subjects of
Northern European descent with MOD, tested 1.2 million
SNPs for association with symptom reduction and remission
for up to 12 weeks of antidepressant therapy. No individual
variant met significance criteria in the main analysis, suggesting antidepressant success to be likely due to numerous
minor genetic effects instead of one primary pathway. However, the analysis was limited by the absence of placebo
groups in any of the three studies as well as by the heterogeneity of the trials, and the authors concluded that larger cohorts of systemically treated and observed subjects were
needed to conclusively test the approach.
Despite the inability to precisely identify the genetic regions
associated with antidepressant response, there is some evidence suggesting genotypic-dosing may be a cost-effective
tool in antidepressant treatment dosing. A one-year retrospective study of antidepressant therapy was conducted by
Winner and colleagues in 2013, where 96 depressive or anxiety disorder subjects were tested for CYP2D6, CYP2Cl 9,
CYP2C9, CYP1A2, SLC6A4 and 5HTR2A genotypes.12 Subjects
had their medication and genotype combinations categorized
as "red-bin," "yellow-bin" or "green-bin" based on the degree
of caution and monitoring required as developed by the AssureRx Health GeneSight, a genotype interpretive report.13
Nine subjects were categorized as red bin, with 48 yellow
and 39 green. Compared to the green or yellow bin, subjects
with a medication in the red bin had 69 percent more total
health care visits during the year (p= 0.014). Also, nonpsychiatric medical visits were 67 percent higher for the red bin
(p= 0.039). While red bin assignment was associated with
greater numbers of psychiatric medications, there was no
correlation between the number of drugs taken and any of
the dependent measures, suggesting increase in health care
utilization was directly related to red bin status. The authors
concluded that pharmacogenomic information can better
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fied by medication prescribed or genetic profile, so extrapo-------------------------------------------------------------------

define treatments and increase therapeutic response as well
as decrease costs.

A 2015 study by Singh and colleagues provided buccal swabs
for DNA analysis to 148 subjects with MOD, but only half
were randomized to genotypic testing for CYP2D6, CYP2C19
and ABCBl polymorphisms with dosing guided by the results.14 Remission rates were assessed by the Hamilton Depression Rating Scale (HORS) every four weeks for 12 weeks,
with rating blinded to treatment groups. Remission from
MOD was 2.52 times more likely with the guided treatment
(95 percent confidence interval (Cl): 1.71-3.73, p<0.0001),
while the unguided group was 1.13 times more likely to
experience treatment intolerability issues (95 percent Cl:
1.01-1.25; p=0.0272). The guided group also had significantly lower risk of requiring sick leave (4 percent versus 15 percent, p=0.0272) and shorter length of leave (4.3 days versus
7.7 days, p=0.014). However, the trial results were not strati-

lation of findings to specific drugs or polymorphisms is not
possible.

Genotypic Guidelines
There are currently no dosing guidelines for ABCBl genotypes, but the Clinical Pharmacogenetics Implementation
Consortium (CPIC) has published guidelines for SSR!s and
TCAs based on CYP2D6 and CYP2C19 genotypes.7,s Their recommendations are compiled in Table 2 and Table 3.
Conclusion
Major depressive disorder is one of the most common mental
illnesses in the United States. A large range of therapeutic
options, significant adverse effects and a complex
dose-response relationship contribute to the uncertainty in
optimizing antidepressant therapy. Pharmacogenomics has
attempted to explain some of the variability observed, but

Table 2. CYP2D6 Phenotypic Guidelines for Antidepressant Drugs.6, 7
Poor Metabolizers

Drug

Intermediate
Metabolizers

Ultra-rapid
Metabolizers

Extensive
Metabolizers

TCAs:
Amitriptyline,
Nortriptyline,
Clomipramine,
Desipramine,
Imipramine,
Trimipramine

*4/*4,*4/*5,*5/*5,*4/*6
Avoid due to potential for
side effects, consider
alternatives not metabolized by CYP2D6. If used,
consider 50% reduction of
recommended starting
dose (S).

*4/*10, *5/*41
Consider 25%
reduction of
recommended
starting dose (M).

*1/*1,*1/*2,*2/*2,
*1/*41, *l/*4, *2/*5,
*10/*10
Initiate therapy
with recommended
starting dose (S).

*lj*lxN, *lj*2xN
Avoid due to potential
lack of efficacy,
consider alternatives
not metabolized by
CYP2D6. !fused,
consider increasing
starting dose (S).

Fluvoxamine

*3/*4,*4/*4, *5/*5, *5/*6
Consider a 25-50%
reduction of
recommended starting
dose or use an alternative
drug not metabolized by
CYP2D6 (0).

*4/*10,*4/*41, *5/*9
Initiate therapy
with recommended
starting dose (M).

*1/*l,*1/*2,*1/*4,
*1/*5, *1/*9, *1/*41,
*2/*2,*41/*41
Initiate therapy with
recommended
starting dose (S).

*lf*lxN, *lf*2xN, *2/
*2xN
No recommendation
due to lack of evidence
(0).

Paroxetine

*3/*4,*4/*4, *5/*5, *5/*6
Select alternative drug not
metabolized by CYP2D6,
or consider a 50%
reduction of
recommended starting
dose (0).

*4/*10,*4/*41, *5/*9
Initiate therapy
with recommended
starting dose (M).

*1/*l,*1/*2,*1/*4,
*1/*5,*1/*9,*1/*41,
*2/*2,*41/*41
Initiate therapy with
recommended
starting dose (S).

*1/*lxN, *1/*2xN, *2/
*2xN
Select alternative drug
not metabolized by
CYP2D6 (SJ.

Recommendation strength: S-strong, M-moderate, W-weak, 0-optional
Adapted with permission from John Wiley and Sons, Inc., from Hicks et al. Clin Pharmacol Ther. 2013 May;93(5):402-8.© 2013 American
Society for Clinical Pharmacology and Therapeutics.
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Table 3. CYP2C19 Phenotypic Guidelines for Antidepressant Drugs. 6•7

Drug

Poor Metabolizers

Intermediate
Metabolize rs

Extensive
Metabolize rs

Ultra-rapid
Metabolfzers

SSRis:
Citalopram,
Escitalopram,
Sertraline

*2/*2,*2/*3,*3/*3
Consider a 50% reduction
of starting dose or select
alternative drug not
metabolized by CYP2C19
(M).

*1/*2,*1/*3,*2/*17
Initiate therapy with
recommended starting dose (S).

*1/*1
Initiate therapy with
recommended
starting dose (S).

*17 /*17, *1/*17
Initiate therapy with
recommended
starting dose,
consider alternative
drug not
metabolized by
CYP2C19 (M).

TCAs:
Amitriptyline,
Clomipramine,
Imipramine,
Trimipramine

*2/*2,*2/*3,*3/*3
Consider a 50% reduction
of recommended starting
dose or select alternative
drug not metabolized by
CYP2C19 (0).

*1/*2,*1/*3,*2/*17
Initiate therapy with
recommended starting dose (S).

*1/*1
Initiate therapy with
recommended
starting dose (S).

*17/*17, *1/*17
Initiate therapy with
recommended
starting dose,
consider alternative
drug not
metabolized by
CYP2C19 (0).

Recommendation strength: S-strong, M-moderate, W-weak, 0-optional
Adapted with permission from John Wiley and Sons, Inc., from Hicks et al. Clin Pharmacol Ther. 2015 Aug;98(2):127-34. © 2015 American
Society for Clinical Pharmacology and Therapeutics, and Hicks et al. Clin Pharmacol Ther. 2013 May;93(5):402-8.© 2013 American Society
for Clinical Pharmacology and Therapeutics.

current data are unable to provide specific mechanisms. The
metabolic enzyme activity of CYP2D6 and CYP2C19 has been
shown to be connected to the plasma concentration of many
antidepressants, but the clinical response to antidepressants
does not necessarily have a linear relationship to drug concentration; guidelines for CYP2D6 and CYP2C19-based dosing
are largely proactive and unconfirmed. While ABCBl has
been examined for its involvement in drug delivery to the
brain, there is inconclusive evidence on which variations are
significantly associated with antidepressant response.
Further studies are needed to identify significant genetic
pathways. While early trials already indicated possible efficacy of genotype-guided drug therapy, further analyses will be
required to confirm its benefit. Given the high long-term cost
of treating depression, and further health care costs if treatment fails, even modest improvements in patient response
could justify the use of genotyping.
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